
SAFFRON found longer progression-free and overall survival with savolitinib plus osimertinib than with chemotherapy in a defined lung cancer group.
HUTCHMED said its SAFFRON Phase III trial found that ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% versus chemotherapy. The results were presented at the ESMO Congress and published in The New England Journal of Medicine.
The trial enrolled patients with advanced or metastatic EGFR-mutated non-small cell lung cancer, high MET levels and disease progression after TAGRISSO treatment. Median progression-free survival was 7.6 months with the drug combination, compared with 5.4 months with chemotherapy.
Median overall survival reached 17.8 months with the combination and 12.9 months with chemotherapy. HUTCHMED said the combination reduced the risk of death by 32%. The trial’s one-year overall survival rates were 70% and 53%, respectively.
Grade 3 or higher treatment-emergent adverse events occurred in 64% of patients receiving the combination and 63% of those on chemotherapy. HUTCHMED described the combination’s safety profile as manageable, with no new safety concerns.
The company said a US drug application has been submitted for the treatment. Submissions in Europe and Japan are progressing as planned, according to HUTCHMED.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.